1. Home
  2. SWTX vs ALIT Comparison

SWTX vs ALIT Comparison

Compare SWTX & ALIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWTX
  • ALIT
  • Stock Information
  • Founded
  • SWTX 2017
  • ALIT 2017
  • Country
  • SWTX United States
  • ALIT United States
  • Employees
  • SWTX N/A
  • ALIT N/A
  • Industry
  • SWTX Biotechnology: Pharmaceutical Preparations
  • ALIT Business Services
  • Sector
  • SWTX Health Care
  • ALIT Consumer Discretionary
  • Exchange
  • SWTX Nasdaq
  • ALIT Nasdaq
  • Market Cap
  • SWTX 3.5B
  • ALIT 3.3B
  • IPO Year
  • SWTX 2019
  • ALIT N/A
  • Fundamental
  • Price
  • SWTX $46.67
  • ALIT $5.33
  • Analyst Decision
  • SWTX Buy
  • ALIT Strong Buy
  • Analyst Count
  • SWTX 7
  • ALIT 8
  • Target Price
  • SWTX $56.86
  • ALIT $9.94
  • AVG Volume (30 Days)
  • SWTX 4.9M
  • ALIT 8.2M
  • Earning Date
  • SWTX 05-09-2025
  • ALIT 05-08-2025
  • Dividend Yield
  • SWTX N/A
  • ALIT 2.25%
  • EPS Growth
  • SWTX N/A
  • ALIT N/A
  • EPS
  • SWTX N/A
  • ALIT N/A
  • Revenue
  • SWTX $219,670,000.00
  • ALIT $2,321,000,000.00
  • Revenue This Year
  • SWTX $79.29
  • ALIT $2.53
  • Revenue Next Year
  • SWTX $70.79
  • ALIT $4.02
  • P/E Ratio
  • SWTX N/A
  • ALIT N/A
  • Revenue Growth
  • SWTX 730.42
  • ALIT N/A
  • 52 Week Low
  • SWTX $28.21
  • ALIT $4.49
  • 52 Week High
  • SWTX $62.00
  • ALIT $8.93
  • Technical
  • Relative Strength Index (RSI)
  • SWTX 60.85
  • ALIT 44.36
  • Support Level
  • SWTX $46.21
  • ALIT $5.36
  • Resistance Level
  • SWTX $46.77
  • ALIT $5.57
  • Average True Range (ATR)
  • SWTX 0.15
  • ALIT 0.13
  • MACD
  • SWTX -0.05
  • ALIT -0.03
  • Stochastic Oscillator
  • SWTX 85.71
  • ALIT 11.89

About SWTX SpringWorks Therapeutics Inc.

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.

About ALIT Alight Inc.

Alight Inc is a technology-enabled services company delivering human capital management solutions to many of complex organizations. This includes the implementation and administration of employee benefits (e.g., health, wealth and leaves benefits) solutions, currently operates under one reportable segment, Employer Solutions. The Company completed the Divestiture of Alight's Professional Services segment and Alight's Payroll & HCM Outsourcing business within the Employer Solutions segment. The company operates in USA states and International market too.

Share on Social Networks: